Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Brain Neoplasms 4Breast Neoplasms 2Recurrence 1Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Lymphoma 1Leukemia 1Glioblastoma 1Ependymoma 1Disease 1Central Nervous System Neoplasms 1

Interventions

Psychiatric Rehabilitation 5Melphalan 5Cyclophosphamide 5Methylprednisolone 4Flow Cytometry 4Busulfan 4Early Intervention, Educational 3Antilymphocyte Serum 3Alemtuzumab 3fludarabine phosphate 2Radiotherapy 2Immunologic Techniques 2Filgrastim 2Azacitidine 2thymoglobulin 1tanespimycin 1sargramostim 1ruxolitinib 1rucaparib 1pembrolizumab 1neratinib 1ixabepilone 1fosphenytoin 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1cc-486 1bempegaldesleukin 1aldesleukin 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × neratinib × CNS × Clear all
NCT02932280 2025-12-05

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
14 enrolled
CNSLymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphoma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡